Tricida (TCDA) Reports Q4 Loss of $0.66/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Tricida (TCDA) Reports Q4 Loss of $0.66/Share

Tricida Announces Fourth Quarter and Full-Year 2018 Financial Results

March 28, 2019 7:00 AM EDT

Webcast Today at 8:00 am Eastern Time

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tricida,Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three months and full year ended December 31, 2018 and provided an update on key initiatives.

Recent Highlights

Announced today, initial topline data analyses of the TRCA-301E trial, a placebo-controlled, blinded, 40-week extension... More